Legal Investigations Underway Against Novo Nordisk by Faruqi & Faruqi for Investor Claims
Legal Investigations Underway Against Novo Nordisk by Faruqi & Faruqi for Investor Claims
Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into potential claims on behalf of investors of Novo Nordisk A/S, commonly referred to as Novo Nordisk. This investigation stems from concerns regarding the company's alleged violations of federal securities laws related to its REDEFINE-1 trial protocol.
The impetus for the probe follows a significant announcement made by Novo Nordisk on December 20, 2024. In this release, the company disclosed that their trial for CagriSema, aimed at achieving weight loss, yielded an average of only 22.7% after a period of 68 weeks. This outcome was notably affected by the company's previously undisclosed
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.